Roche outlined a strategy to become an end-to-end oncology solutions provider by combining diagnostic instruments, testing workflows and new capabilities via acquisitions. At its diagnostics day, Roche discussed pending deals including PathAI (for AI-assisted pathology and companion diagnostics) and Saga Diagnostics/Foundation Medicine’s Pathlight MRD technology for monitoring.